## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

## Listing Of Claims

1-108. (canceled)

109. (currently amended) A compound consists of a formula selected from the group consisting of the formula

wherein

 $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, thio, cyano, nitro, and a carbonyl group, each substituted or unsubstituted;

 $R_{14}$  is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or  $R_{14}$  is a substituent that is convertible in vivo to hydrogen:

M is selected from the group consisting of trifluoroacetyl (-C(O)-CF<sub>3</sub>),
-NH-P(O)OH-CH<sub>3</sub>, sulfonamides (-SO<sub>2</sub>NH<sub>2</sub>), hydroxysulfonamides (-SO<sub>2</sub>NHOH), thiols(-SH),
and carbonyl groups having the formula -C(O)-R<sub>13</sub> wherein R<sub>13</sub> is hydroxylamino, hydroxyl,
amino, alkylamino, and an alkoxy group, each substituted or unsubstituted; and

L is a substituent providing between 0-10 2-10 atoms separation between the M substituent and the remainder of the compound, wherein the 2-10 atoms are all carbon atoms.

110. (previously presented) The compound according to claim 109, wherein the compound consists of a formula selected from the group consisting of

111. (previously presented) The compound according to claim 109, wherein the compound consists of a formula selected from the group consisting of

- 112. (currently amended) The compound according to claim 109, wherein  $R_{14}$  is <u>hydrogen</u>. selected from the group consisting of hydrogen and a substituent that is convertible in vivo to hydrogen.
- 113. (previously presented) The compound according to claim 109, wherein R<sub>14</sub> is a substituted or unsubstituted C<sub>1-6</sub> alkyl.
- 114. (previously presented) The compound according to claim 109, wherein  $R_{14}$  is a substituted or unsubstituted  $-C(O)C_{1-6}$  alkyl.
- 115. (previously presented) The compound according to claim 109, wherein R<sub>14</sub> is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.
- 116. (previously presented) The compound according to claim 109, wherein at least one of  $R_2$ ,  $R_3$ ,  $R_4$ , or  $R_5$  is fluoro.

## 117. (canceled)

118. (previously presented) The compound according to claim 109, wherein M is selected from the group consisting of:

- 119. (previously presented) The compound according to claim 109, wherein M is a hydroxamic acid moiety.
- 120. (previously presented) The compound according to claim 109, wherein -L-M is

121. (currently amended) A compound of a formula selected from the group consisting of the formula:

wherein

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are each independently selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, cyano and nitro, each substituted or unsubstituted;

 $R_{14}$  is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or  $R_{14}$  is a substituent that is convertible in vivo to hydrogen;

M is selected from the group consisting of trifluoroacetyl (-C(O)-CF<sub>3</sub>),
-NH-P(O)OH-CH<sub>3</sub>, sulfonamides (-SO<sub>2</sub>NH<sub>2</sub>), hydroxysulfonamides (-SO<sub>2</sub>NHOH), thiols(-SH),
and carbonyl groups having the formula -C(O)-R<sub>13</sub> wherein R<sub>13</sub> is hydroxylamino, hydroxyl,
amino, alkylamino, and an alkoxy group, each substituted or unsubstituted; and

L is a substituent providing between 2-10 atoms separation between the M substituent and the remainder of the compound, wherein the 2-10 atoms are all carbon atoms.

122. (previously presented) The compound according to claim 121, wherein the compound consists of a formula selected from the group consisting of

123. (previously presented) The compound according to claim 121, wherein the compound consists of a formula selected from the group consisting of

124. (currently amended) The compound according to claim 121, wherein  $R_{14}$  is <u>hydrogen</u>. selected from the group consisting of hydrogen and a substituent that is convertible *in vivo* to hydrogen.

- 125. (previously presented) The compound according to claim 121, wherein R<sub>14</sub> is a substituted or unsubstituted C<sub>1-5</sub> alkyl.
- 126. (previously presented) The compound according to claim 121, wherein R<sub>14</sub> is a substituted or unsubstituted -C(O)C<sub>1.6</sub> alkyl.
- 127. (previously presented) The compound according to claim 121, wherein R<sub>14</sub> is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.
- 128. (previously presented) The compound according to claim 121, wherein at least one of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, or R<sub>5</sub> is fluoro.
- 129. (canceled)
- 130. (previously presented) The compound according to claim 121, wherein M is selected from the group consisting of:

- 131. (previously presented) The compound according to claim 121, wherein M is a hydroxamic acid moiety.
- 132. (previously presented) The compound according to claim 121, wherein -L-M is

## 133. (currently amended) A compound of a formula selected from the group consisting of the formula:

wherein

 $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are each independently selected from the group consisting of hydrogen, halo,  $(C_{1-10})$ alkyl,  $(C_{1-10})$ alkoxy,  $(C_{5-12})$ aryl,  $(C_{5-12})$ heteroaryl, cyano, and nitro, each substituted or unsubstituted;

R<sub>14</sub> is selected from the group consisting of hydrogen, halo, alkyl, alkoxy, aryl, heteroaryl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, amino, and a carbonyl group, each substituted or unsubstituted, or R<sub>14</sub> is a substituent that is convertible in wive to hydrogen:

M is selected from the group consisting of

and

L is selected from the group consisting of (E) isomer of -CH=CH-, (Z) isomer or -CH=CH-, and mixtures of (E) and (Z) isomers of -CH=CH-.

134. (previously presented) The compound according to claim 133, wherein the compound consists of a formula selected from the group consisting of

135. (previously presented) The compound according to claim 133, wherein the compound consists of a formula selected from the group consisting of

$$\begin{array}{c} R_2 \\ R_3 \\ R_4 \\ R_5 \\ \end{array} \\ NR_{14} \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_5 \\ \end{array} \\ NR_{14} \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_3 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_4 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_2 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_3 \\ R_6 \\ \end{array} \\ \begin{array}{c} R_4 \\ R_6 \\ \end{array}$$

- 136. (currently amended) The compound according to claim 133, wherein R<sub>14</sub> is <u>hydrogen</u>. selected from the group-consisting of hydrogen and a substituent that is convertible in vivo to hydrogen.
- 137. (previously presented) The compound according to claim 133, wherein R<sub>14</sub> is a substituted or unsubstituted C<sub>1.6</sub> alkyl.
- 138. (previously presented) The compound according to claim 133, wherein R<sub>14</sub> is a substituted or unsubstituted -C(O)C<sub>1.6</sub> alkyl.
- 139. (previously presented) The compound according to claim 133, wherein R<sub>14</sub> is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, acetyl, and BOC.
- 140. (previously presented) The compound according to claim 133, wherein at least one of R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, or R<sub>5</sub> is fluoro.

141-142. (canceled)

- 143. (previously presented) The compound according to claim 133, wherein M is a hydroxamic acid moiety.
- 144. (previously presented) The compound according to claim 133, wherein -L-M is

145. (previously presented) The compound according to claim 109, wherein M is

146. (previously presented) The compound according to claim 109, wherein M is

147. (previously presented) The compound according to claim 109, wherein M is

148. (previously presented) The compound according to claim 109, wherein M is

149. (previously presented) The compound according to claim 109, wherein M is

150. (previously presented) The compound according to claim 109, wherein M is

151. (previously presented) The compound according to claim 109, wherein M is

152. (previously presented) The compound according to claim 109, wherein M is

153. (previously presented) The compound according to claim 109, wherein M is

154. (previously presented) The compound according to claim 109, wherein M is

155. (previously presented) The compound according to claim 121, wherein M is

156. (previously presented) The compound according to claim 121, wherein M is

157. (previously presented) The compound according to claim 121, wherein M is

158. (previously presented) The compound according to claim 121, wherein M is

159. (previously presented) The compound according to claim 121, wherein M is

160. (previously presented) The compound according to claim 121, wherein M is

161. (previously presented) The compound according to claim 121, wherein M is

162. (previously presented) The compound according to claim 121, wherein M is

163. (previously presented) The compound according to claim 121, wherein M is

164. (previously presented) The compound according to claim 121, wherein M is

165. (previously presented) The compound according to claim 121, wherein M is

166. (previously presented) The compound according to claim 133, wherein M is

167. (previously presented) The compound according to claim 133, wherein M is

168. (previously presented) The compound according to claim 133, wherein M is

169. (previously presented) The compound according to claim133, wherein M is

170. (previously presented) The compound according to claim 133, wherein M is

171. (previously presented) The compound according to claim 133, wherein M is

172. (previously presented) The compound according to claim 133, wherein M is

173. (previously presented) The compound according to claim 133, wherein M is

174-175. (canceled)

176. (previously presented) The compound according to claim 109, wherein -L-M is

177. (previously presented) The compound according to claim 121, wherein -L-M is